Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 04:00PM ET
4.64
Dollar change
-0.42
Percentage change
-8.30
%
IndexRUT P/E- EPS (ttm)-4.41 Insider Own7.16% Shs Outstand50.63M Perf Week-15.94%
Market Cap238.08M Forward P/E- EPS next Y-0.70 Insider Trans22.80% Shs Float47.64M Perf Month3.34%
Income-217.57M PEG- EPS next Q-0.75 Inst Own93.43% Short Float14.29% Perf Quarter44.55%
Sales100.39M P/S2.37 EPS this Y56.00% Inst Trans-1.52% Short Ratio4.66 Perf Half Y12.90%
Book/sh5.04 P/B0.92 EPS next Y64.05% ROA-35.61% Short Interest6.81M Perf Year-48.79%
Cash/sh4.23 P/C1.10 EPS next 5Y- ROE-76.91% 52W Range1.53 - 12.69 Perf YTD8.67%
Dividend Est.- P/FCF- EPS past 5Y- ROI-43.57% 52W High-63.44% Beta1.82
Dividend TTM- Quick Ratio3.98 Sales past 5Y73.45% Gross Margin72.90% 52W Low202.28% ATR (14)0.49
Dividend Ex-Date- Current Ratio3.98 EPS Y/Y TTM41.77% Oper. Margin-215.87% RSI (14)44.11 Volatility7.42% 9.75%
Employees274 Debt/Eq1.01 Sales Y/Y TTM9.72% Profit Margin-216.73% Recom2.14 Target Price11.80
Option/ShortYes / Yes LT Debt/Eq0.96 EPS Q/Q-84.82% Payout- Rel Volume0.49 Prev Close5.06
Sales Surprise-27.35% EPS Surprise-7.24% Sales Q/Q-80.98% EarningsMar 05 BMO Avg Volume1.46M Price4.64
SMA20-9.66% SMA50-11.27% SMA200-3.46% Trades Volume713,909 Change-8.30%
Date Action Analyst Rating Change Price Target Change
Jan-31-24Upgrade Leerink Partners Market Perform → Outperform $5 → $18
Jan-31-24Downgrade TD Cowen Outperform → Market Perform
Oct-30-23Downgrade Leerink Partners Outperform → Market Perform $6
Oct-12-23Initiated Citigroup Buy $13
Sep-13-23Downgrade Goldman Buy → Neutral $5
Sep-12-23Downgrade Guggenheim Buy → Neutral
Jul-28-23Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $13
Oct-31-22Initiated Guggenheim Buy $30
May-02-22Initiated Goldman Buy $26
Feb-10-22Initiated SVB Leerink Outperform $38
Apr-17-24 11:02AM
Apr-05-24 09:05AM
Apr-01-24 07:30AM
Mar-20-24 05:04PM
Mar-15-24 06:27PM
09:10AM Loading…
Mar-07-24 09:10AM
Mar-05-24 07:53AM
07:00AM
Mar-04-24 08:56AM
Mar-01-24 07:00AM
Feb-27-24 08:00AM
Feb-05-24 04:05PM
06:59AM
Feb-01-24 08:27AM
Jan-31-24 11:11AM
07:01AM Loading…
Jan-30-24 07:01AM
Jan-12-24 12:00PM
Dec-11-23 07:30PM
07:00AM
Dec-06-23 02:00PM
Nov-20-23 12:02PM
06:59AM
Nov-14-23 07:00AM
Nov-10-23 07:00AM
Sep-12-23 07:00AM
06:55AM
Sep-06-23 07:00AM
Aug-24-23 09:00PM
Aug-14-23 07:00AM
Aug-08-23 07:00AM
04:15PM Loading…
Aug-01-23 04:15PM
Jun-14-23 07:00AM
Jun-07-23 07:00AM
May-19-23 06:00AM
May-17-23 07:17AM
May-11-23 12:37PM
May-03-23 04:05PM
May-02-23 04:37PM
10:00AM
May-01-23 07:00AM
Apr-28-23 08:30AM
Apr-17-23 06:59AM
Mar-16-23 04:05PM
Mar-08-23 08:30AM
Mar-03-23 07:00AM
Mar-01-23 09:00AM
Feb-28-23 09:00PM
04:01PM
Feb-10-23 11:13AM
Feb-01-23 07:30AM
Jan-18-23 11:35AM
Jan-09-23 08:00AM
Jan-06-23 09:11AM
Nov-07-22 04:05PM
Nov-03-22 09:06AM
Oct-27-22 07:00AM
Sep-07-22 07:00AM
Aug-31-22 07:30AM
Aug-12-22 06:23AM
Aug-10-22 06:50AM
06:45AM
Aug-04-22 07:02AM
Aug-03-22 07:30AM
Jul-04-22 03:30PM
Jun-06-22 07:30AM
May-12-22 04:05PM
May-04-22 09:10PM
Apr-08-22 04:15PM
Apr-07-22 07:30AM
Mar-22-22 07:00AM
Mar-16-22 08:41AM
Feb-14-22 07:30AM
07:00AM
Feb-11-22 09:58AM
Feb-03-22 01:38PM
Jan-26-22 08:00AM
Jan-11-22 07:00AM
Jan-06-22 07:00AM
Dec-13-21 06:15PM
Dec-01-21 07:00AM
Nov-15-21 10:43AM
Nov-10-21 04:30PM
2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Casdin Capital, LLCDirectorMar 26 '24Buy5.1040,000203,9922,000,000Mar 28 08:29 PM
Casdin Capital, LLCDirectorMar 25 '24Buy5.07330,0001,673,9911,960,000Mar 25 09:44 PM
Casdin Capital, LLCDirectorMar 22 '24Buy5.12147,377754,0691,630,000Mar 25 09:44 PM
Casdin Capital, LLCDirectorMar 21 '24Buy4.90300,0001,470,9901,482,623Mar 25 09:44 PM
Leschly NickPresident and CEOJan 05 '24Sale3.751,5545,8331,085,476Jan 09 04:08 PM
Baird William D IIIChief Operating OfficerJan 05 '24Sale3.751,3805,180161,335Jan 09 04:09 PM
Gregory Philip DChief Scientific OfficerJan 05 '24Sale3.757952,984230,842Jan 09 04:09 PM
Leschly NickPresident and CEOJan 03 '24Sale3.8772,312279,7391,087,030Jan 05 04:30 PM
Baird William D IIIChief Operating OfficerJan 03 '24Sale3.8733,651130,179162,715Jan 05 04:29 PM
Gregory Philip DChief Scientific OfficerJan 03 '24Sale3.8725,61399,084231,637Jan 05 04:30 PM
Leschly NickPresident and CEOAug 22 '23Sale5.499,31251,0901,159,342Aug 24 05:04 PM
Baird William D IIIChief Financial OfficerAug 22 '23Sale5.497,03138,576196,366Aug 24 05:04 PM
Gregory Philip DChief Scientific OfficerAug 22 '23Sale5.496,15933,791257,250Aug 24 05:04 PM
Kynam Capital Management, LP10% OwnerAug 10 '23Buy5.92515,4143,049,2875,953,825Aug 14 08:51 PM
Kynam Global Healthcare Master10% OwnerAug 10 '23Buy5.92515,4143,049,2875,953,825Aug 16 07:11 PM
Kynam Global Healthcare Master10% OwnerAug 10 '23Buy5.9686,414515,0275,142,111Aug 16 07:11 PM
Kynam Capital Management, LP10% OwnerAug 10 '23Buy5.9686,414515,0275,142,111Aug 14 08:51 PM
Leschly NickPresident and CEOAug 03 '23Sale6.139,06055,4991,168,654Aug 07 04:07 PM
Baird William D IIIChief Financial OfficerAug 03 '23Sale6.136,90642,304203,397Aug 07 04:06 PM
Gregory Philip DChief Scientific OfficerAug 03 '23Sale6.133,96624,295263,409Aug 07 04:06 PM